PMID- 28871256
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 8
DP  - 2017
TI  - Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary 
      Peptide Repertoires.
PG  - 984
LID - 10.3389/fimmu.2017.00984 [doi]
LID - 984
AB  - Human leukocyte antigen (HLA)-DR15 is a haplotype associated with multiple 
      sclerosis. It contains the two DRB* genes DRB1*1501 (DR2b) and DRB5*0101 (DR2a). 
      The reported anchor motif of the corresponding HLA-DR molecules was determined in 
      1994 based on a small number of peptide ligands and binding assays. DR2a could 
      display a set of peptides complementary to that presented by DR2b or, 
      alternatively, a similar peptide repertoire but recognized in a different manner 
      by T cells. It is known that DR2a and DR2b share some peptide ligands, although 
      the degree of similarity of their associated peptidomes remains unclear. In 
      addition, the contribution of each molecule to the global peptide repertoire 
      presented by the HLA-DR15 haplotype has not been evaluated. We used mass 
      spectrometry to analyze the peptide pools bound to DR2a and DR2b, identifying 169 
      and 555 unique peptide ligands of DR2a and DR2b, respectively. The analysis of 
      these sets of peptides allowed the refinement of the corresponding binding motifs 
      revealing novel anchor residues that had been overlooked in previous analyses. 
      Moreover, the number of shared ligands between both molecules was low, indicating 
      that DR2a and DR2b present complementary peptide repertoires to T cells. Finally, 
      our analysis suggests that, quantitatively, both molecules contribute to the 
      peptide repertoire presented by cells expressing the HLA-DR15 haplotype.
FAU - Scholz, Erika Margaret
AU  - Scholz EM
AD  - Institut de Biotecnologia i de Biomedicina, Universitat Autonoma de Barcelona, 
      Bellaterra, Spain.
AD  - Immunology Unit, Department of Cell Biology, Physiology and Immunology, 
      Universitat Autonoma de Barcelona, Bellaterra, Spain.
FAU - Marcilla, Miguel
AU  - Marcilla M
AD  - Proteomics Unit, Centro Nacional de Biotecnologia (CSIC), Madrid, Spain.
FAU - Daura, Xavier
AU  - Daura X
AD  - Institut de Biotecnologia i de Biomedicina, Universitat Autonoma de Barcelona, 
      Bellaterra, Spain.
AD  - Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
FAU - Arribas-Layton, David
AU  - Arribas-Layton D
AD  - Benaroya Research Institute at Virginia Mason, Seattle, WA, United States.
FAU - James, Eddie A
AU  - James EA
AD  - Benaroya Research Institute at Virginia Mason, Seattle, WA, United States.
FAU - Alvarez, Inaki
AU  - Alvarez I
AD  - Institut de Biotecnologia i de Biomedicina, Universitat Autonoma de Barcelona, 
      Bellaterra, Spain.
AD  - Immunology Unit, Department of Cell Biology, Physiology and Immunology, 
      Universitat Autonoma de Barcelona, Bellaterra, Spain.
LA  - eng
PT  - Journal Article
DEP - 20170821
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC5566978
OTO - NOTNLM
OT  - binding motif
OT  - human leukocyte antigen-DR
OT  - mass spectrometry
OT  - multiple sclerosis
OT  - peptidome
EDAT- 2017/09/06 06:00
MHDA- 2017/09/06 06:01
PMCR- 2017/01/01
CRDT- 2017/09/06 06:00
PHST- 2017/06/06 00:00 [received]
PHST- 2017/08/02 00:00 [accepted]
PHST- 2017/09/06 06:00 [entrez]
PHST- 2017/09/06 06:00 [pubmed]
PHST- 2017/09/06 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2017.00984 [doi]
PST - epublish
SO  - Front Immunol. 2017 Aug 21;8:984. doi: 10.3389/fimmu.2017.00984. eCollection 
      2017.